Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A1 | P46059 | 2/20 | 0.65 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22804119 | 1.00 | SLC15A1 (0.65) | SLC15A1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL28209173 | 0.88 | SLC15A1 (0.60) | SLC15A1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL7385188 | 0.85 | SLC15A1 (0.59) | SLC15A1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL84418 | 0.84 | SLC15A1 (0.63) | SLC15A1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL6566591 | 0.84 | SLC15A1 (0.63) | SLC15A1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL7207073 | 0.84 | SLC15A1 (0.63) | SLC15A1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL27635124 | 0.83 | SLC15A1 (0.59) | SLC15A1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL8447494 | 0.83 | SLC15A1 (0.59) | SLC15A1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL9781868 | 0.83 | SLC15A1 (0.59) | SLC15A1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL8323575 | 0.83 | SLC15A1 (0.60) | SLC15A1SLC1A3SLC1A2SLC1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109125260-A | Amphipathic polymer is preparing the application in oral drugs | 北京中医药大学 | 2019-01-04 | — | — | CN | claimed |
| WO-2025224463-A1 | DESMURAMYLPEPTIDE ANALOGUE MONOESTER | Imhotex Limited (GB) | 2025-10-30 | — | — | WO | disclosed |
| WO-2025049064-A9 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | SIGNPATH PHARMA INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025049064-A2 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | SIGNPATH PHARMA INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-119522110-A | Novel linker compounds and ligand-drug conjugates thereof | 特里奥尔株式会社 | 2025-02-25 | — | — | CN | disclosed |
| CN-119451701-A | Compounds comprising self-destructing groups and ligand-drug conjugates comprising the same | 特里奥尔株式会社 | 2025-02-14 | — | — | CN | disclosed |
| EP-4472668-A1 | PHOSPHORAMIDATE-BASED PSMA-TARGETED SMALL-MOLECULE DRUG CONJUGATES | Cancer Targeted Technology LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2024224089-A1 | DESMURAMYLPEPTIDE MONOESTERS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2024-10-31 | — | — | WO | disclosed |
| US-20240270765-A2 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | SIGNPATH PHARMA INC. | 2024-08-15 | — | — | US | disclosed |
| US-20240025928-A1 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | SIGNPATH PHARMA INC (US) | 2024-01-25 | — | — | US | disclosed |
| EP-0282891-B1 | New thymopentin retro-inverso analogs and fragments thereof, a process of preparation of the new compounds and the intermediates obtained therein | ENIRICERCHE SPA (IT) | 1994-01-26 | — | — | EP | disclosed |
| EP-0565631-A1 | ANTI-VIRAL COMPOUNDS. | MERRELL DOW PHARMA (US) | 1993-10-20 | — | — | EP | disclosed |
| WO-1993013066-A1 | CYCLIC AMIDES OF 3-AMINO-2-HYDROXY-CARBOXYLIC ACIDS AS HIV-PROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1993-07-08 | — | — | WO | disclosed |
| WO-1993005026-A1 | PEPTIDE ISOTERS CONTAINING A HETEROCYCLE AS H.I.V. INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-03-18 | — | — | WO | disclosed |
| WO-1992012123-A1 | ANTI-VIRAL COMPOUNDS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-07-23 | — | — | WO | disclosed |
| US-4880780-A | RESPIRATORY SYSTEM DISORDERS | ICI AMERICAS INC. (US) | 1989-11-14 | — | — | US | disclosed |
| EP-0282891-A2 | New thymopentin retro-inverso analogs and fragments thereof, a process of preparation of the new compounds and the intermediates obtained therein | ENIRICERCHE S.p.A. (IT) | 1988-09-21 | — | — | EP | disclosed |
| US-4369178-A | Glucosamine peptide derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1983-01-18 | — | — | US | disclosed |
| EP-0014984-A1 | Glucosamine-peptide derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1980-09-03 | — | — | EP | disclosed |
| US-4028315-A | Solid phase synthesis of peptides | E. R. SQUIBB & SONS, INC. (US) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025928-A1 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | CPT1B, FABP3, NR1H2 | SLC15A1 2352/4885SLC1A3 2725/4885SLC1A2 2775/4885 |
| US-20240270765-A2 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | CPT1B, FABP3, NR1H2 | SLC15A1 2352/4885SLC1A3 2725/4885SLC1A2 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.